Mosquito-borne Diseases Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under development and key players involved in therapeutic development for West Nile virus infections, Japanese encephalitis, yellow fever and malaria. It also features dormant and discontinued products.

West Nile infection, Japanese encephalitis and yellow fever are all caused by flaviviruses, whereas malaria is caused by a parasite (Plasmodium). Symptoms of West Nile infection include a fever, headache, body aches, skin rash, and swollen lymph glands. There are 18 products in development for this indication.

Japanese encephalitis affects the membranes around the brain. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. There are 17 products in development for this indication.

Yellow fever is an acute systemic illness (hemorrhagic fever). Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There are 15 products in development for this indication.

Malaria is a life-threatening blood disease. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. There are 206 products in development for this indication.

Molecular targets acted on by products in development for mosquito-borne diseases include interferon receptors, toll-like receptors and pathogen proteins such as Plasmodium falciparum merozoite surface proteins. Companies operating in this pipeline space include Sanaria, Medigen and Ology Bioservices.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

4SC AG

AbbVie Inc

Abivax SA

Adimmune Corp

Agilvax Inc

Akshaya Bio Inc

AlfaSigma SpA

Allergy Therapeutics Plc

Altimmune Inc

Artificial Cell Technologies Inc

AstraZeneca Plc

Bavarian Nordic A/S

Bharat Biotech Ltd

BioCryst Pharmaceuticals Inc

Cadila Healthcare Ltd

Carna Biosciences Inc

Celgene Corp

CEL-SCI Corp

Cilian AG

Curevac AG

Daiichi Sankyo Co Ltd

DesignMedix Inc

DMG Deutsche Malaria GmbH

Eisai Co Ltd

Emergex Vaccines Ltd

Ennaid Therapeutics LLC

Fosun International Ltd

GenVec Inc

Genzyme Corp

GeoVax Labs Inc

GlaxoSmithKline Plc

Hager Biosciences LLC

Hawaii Biotech Inc

Hemispherx Biopharma Inc

iBio Inc

Ichor Medical Systems Inc

ID Pharma Co Ltd

Immunovaccine Inc

Indian Immunologicals Ltd

IPCA Laboratories Ltd

Kancera AB

Kineta Inc

Kymab Ltd

Lipocure Ltd

Livzon Pharmaceutical Group Inc

LondonPharma Ltd

Marinomed Biotech AG

Merck KGaA

Microbiotix Inc

Mitsubishi Tanabe Pharma Corp

Mymetics Corp

Nobelpharma Co Ltd

Novartis AG

Ology Bioservices Inc

Osivax SAS

Otsuka Holdings Co Ltd

Panacea Biotec Ltd

PaxVax Inc

Pfizer Inc

Plex Pharmaceuticals Inc

Protein Potential LLC

Rodos BioTarget GmbH

Sanaria Inc

Sanofi

SBI Pharmaceuticals Co Ltd

Sihuan Pharmaceutical Holdings Group Ltd

Sinovac Biotech Ltd

Takeda Pharmaceutical Co Ltd

Theravectys SA

Titan Pharmaceuticals Inc

Valneva SE

VLP Biotech Inc

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Mosquito-borne Diseases Report Coverage 8

2.2 West Nile Virus Infections - Overview 8

2.3 Japanese Encephalitis - Overview 8

2.4 Yellow Fever - Overview 8

2.5 Malaria - Overview 8

3 Therapeutics Development 9

3.1 West Nile Virus Infections 9

3.2 Japanese Encephalitis 14

3.3 Yellow Fever 18

3.4 Malaria 22

4 Therapeutics Assessment 38

4.1 West Nile Virus Infections 38

4.2 Japanese Encephalitis 44

4.3 Yellow Fever 47

4.4 Malaria 53

5 Companies Involved in Therapeutics Development 62

5.1 West Nile Virus Infections 62

5.2 Japanese Encephalitis 65

5.3 Yellow Fever 70

5.4 Malaria 74

6 Dormant Projects 102

6.1 West Nile Virus Infections 102

6.2 Japanese Encephalitis 104

6.3 Yellow Fever 105

6.4 Malaria 106

7 Discontinued Products 114

7.1 Japanese Encephalitis 114

7.2 Malaria 114

8 Product Development Milestones 116

8.1 West Nile Virus Infections 116

8.2 Yellow Fever 121

8.3 Malaria 124

9 Appendix 141

9.1 Methodology 141

9.2 Coverage 141

9.3 Secondary Research 141

9.4 Primary Research 141

9.5 Expert Panel Validation 141

9.6 Contact Us 142

9.7 Disclaimer 142

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for West Nile Virus Infections 9

Table 2: Number of Products under Development by Companies, West Nile Virus Infections 10

Table 3: Number of Products under Development by Universities/Institutes, West Nile Virus Infections 11

Table 4: Products under Development by Companies, West Nile Virus Infections 12

Table 5: Products under Development by Universities/Institutes, West Nile Virus Infections 13

Table 6: Number of Products under Development for Japanese Encephalitis 14

Table 7: Number of Products under Development by Companies, Japanese Encephalitis 15

Table 8: Number of Products under Development by Universities/Institutes, Japanese Encephalitis 16

Table 9: Products under Development by Companies, Japanese Encephalitis 17

Table 10: Products under Development by Universities/Institutes, Japanese Encephalitis 17

Table 11: Number of Products under Development for Yellow Fever 18

Table 12: Number of Products under Development by Companies, Yellow Fever 19

Table 13: Number of Products under Development by Universities/Institutes, Yellow Fever 20

Table 14: Products under Development by Companies, Yellow Fever 21

Table 15: Products under Development by Universities/Institutes, Yellow Fever 21

Table 16: Number of Products under Development for Malaria 22

Table 17: Number of Products under Development by Companies, Malaria 24

Table 18: Number of Products under Development by Universities/Institutes, Malaria 27

Table 19: Products under Development by Companies, Malaria 29

Table 20: Products under Development by Universities/Institutes, Malaria 33

Table 21: Number of Products by Stage and Target, West Nile Virus Infections 39

Table 22: Number of Products by Stage and Mechanism of Action, West Nile Virus Infections 40

Table 23: Number of Products by Stage and Route of Administration, West Nile Virus Infections 42

Table 24: Number of Products by Stage and Molecule Type, West Nile Virus Infections 43

Table 25: Number of Products by Stage and Target, Japanese Encephalitis 44

Table 26: Number of Products by Stage and Mechanism of Action, Japanese Encephalitis 44

Table 27: Number of Products by Stage and Route of Administration, Japanese Encephalitis 45

Table 28: Number of Products by Stage and Molecule Type, Japanese Encephalitis 47

Table 29: Number of Products by Stage and Target, Yellow Fever 48

Table 30: Number of Products by Stage and Mechanism of Action, Yellow Fever 50

Table 31: Number of Products by Stage and Route of Administration, Yellow Fever 51

Table 32: Number of Products by Stage and Molecule Type, Yellow Fever 53

Table 33: Number of Products by Stage and Target, Malaria 54

Table 34: Number of Products by Stage and Mechanism of Action, Malaria 57

Table 35: Number of Products by Stage and Route of Administration, Malaria 59

Table 36: Number of Products by Stage and Molecule Type, Malaria 61

Table 37: West Nile Virus Infections – Pipeline by CEL-SCI Corp 62

Table 38: West Nile Virus Infections – Pipeline by Ennaid Therapeutics LLC 62

Table 39: West Nile Virus Infections – Pipeline by Hawaii Biotech Inc 63

Table 40: West Nile Virus Infections – Pipeline by Hemispherx Biopharma Inc 63

Table 41: West Nile Virus Infections – Pipeline by Kineta Inc 64

Table 42: West Nile Virus Infections – Pipeline by Ology Bioservices Inc 64

Table 43: West Nile Virus Infections – Pipeline by Plex Pharmaceuticals Inc 65

Table 44: Japanese Encephalitis – Pipeline by Abivax SA 65

Table 45: Japanese Encephalitis – Pipeline by Adimmune Corp 66

Table 46: Japanese Encephalitis – Pipeline by Cadila Healthcare Ltd 66

Table 47: Japanese Encephalitis – Pipeline by Ennaid Therapeutics LLC 67

Table 48: Japanese Encephalitis – Pipeline by Indian Immunologicals Ltd 67

Table 49: Japanese Encephalitis – Pipeline by Kineta Inc 68

Table 50: Japanese Encephalitis – Pipeline by Livzon Pharmaceutical Group Inc 68

Table 51: Japanese Encephalitis – Pipeline by Panacea Biotec Ltd 69

Table 52: Japanese Encephalitis – Pipeline by Sinovac Biotech Ltd 69

Table 53: Yellow Fever – Pipeline by Bavarian Nordic A/S 70

Table 54: Yellow Fever – Pipeline by BioCryst Pharmaceuticals Inc 71

Table 55: Yellow Fever – Pipeline by Emergex Vaccines Ltd 71

Table 56: Yellow Fever – Pipeline by Ennaid Therapeutics LLC 71

Table 57: Yellow Fever – Pipeline by iBio Inc 72

Table 58: Yellow Fever – Pipeline by Ology Bioservices Inc 72

Table 59: Yellow Fever – Pipeline by Sihuan Pharmaceutical Holdings Group Ltd 73

Table 60: Yellow Fever – Pipeline by Valneva SE 73

Table 61: Malaria – Pipeline by 4SC AG 74

Table 62: Malaria – Pipeline by AbbVie Inc 75

Table 63: Malaria – Pipeline by Agilvax Inc 75

Table 64: Malaria – Pipeline by Akshaya Bio Inc 75

Table 65: Malaria – Pipeline by AlfaSigma SpA 76

Table 66: Malaria – Pipeline by Allergy Therapeutics Plc 76

Table 67: Malaria – Pipeline by Altimmune Inc 77

Table 68: Malaria – Pipeline by Artificial Cell Technologies Inc 77

Table 69: Malaria – Pipeline by AstraZeneca Plc 78

Table 70: Malaria – Pipeline by Bharat Biotech Ltd 78

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for West Nile Virus Infections 9

Figure 2: Number of Products under Development by Companies, West Nile Virus Infections 10

Figure 3: Number of Products under Development by Universities/Institutes, West Nile Virus Infections 11

Figure 4: Number of Products under Development for Japanese Encephalitis 14

Figure 5: Number of Products under Development by Companies, Japanese Encephalitis 15

Figure 6: Number of Products under Development by Universities/Institutes, Japanese Encephalitis 16

Figure 7: Number of Products under Development for Yellow Fever 18

Figure 8: Number of Products under Development by Companies, Yellow Fever 19

Figure 9: Number of Products under Development by Universities/Institutes, Yellow Fever 20

Figure 10: Number of Products under Development for Malaria 22

Figure 11: Number of Products under Development by Companies, Malaria 23

Figure 12: Number of Products under Development by Universities/Institutes, Malaria 26

Figure 13: Number of Products by Targets, West Nile Virus Infections 38

Figure 14: Number of Products by Stage and Targets, West Nile Virus Infections 38

Figure 15: Number of Products by Mechanism of Actions, West Nile Virus Infections 39

Figure 16: Number of Products by Stage and Mechanism of Actions, West Nile Virus Infections 40

Figure 17: Number of Products by Routes of Administration, West Nile Virus Infections 41

Figure 18: Number of Products by Stage and Routes of Administration, West Nile Virus Infections 41

Figure 19: Number of Products by Molecule Types, West Nile Virus Infections 42

Figure 20: Number of Products by Stage and Molecule Types, West Nile Virus Infections 43

Figure 21: Number of Products by Routes of Administration, Japanese Encephalitis 44

Figure 22: Number of Products by Stage and Routes of Administration, Japanese Encephalitis 45

Figure 23: Number of Products by Molecule Types, Japanese Encephalitis 46

Figure 24: Number of Products by Stage and Molecule Types, Japanese Encephalitis 46

Figure 25: Number of Products by Targets, Yellow Fever 47

Figure 26: Number of Products by Stage and Targets, Yellow Fever 48

Figure 27: Number of Products by Mechanism of Actions, Yellow Fever 49

Figure 28: Number of Products by Stage and Mechanism of Actions, Yellow Fever 49

Figure 29: Number of Products by Routes of Administration, Yellow Fever 50

Figure 30: Number of Products by Stage and Routes of Administration, Yellow Fever 51

Figure 31: Number of Products by Molecule Types, Yellow Fever 52

Figure 32: Number of Products by Stage and Molecule Types, Yellow Fever 52

Figure 33: Number of Products by Targets, Malaria 53

Figure 34: Number of Products by Stage and Targets, Malaria 54

Figure 35: Number of Products by Top 10 Mechanism of Actions, Malaria 56

Figure 36: Number of Products by Stage and Mechanism of Actions, Malaria 56

Figure 37: Number of Products by Routes of Administration, Malaria 58

Figure 38: Number of Products by Stage and Routes of Administration, Malaria 59

Figure 39: Number of Products by Top 10 Molecule Types, Malaria 60

Figure 40: Number of Products by Stage and Top 10 Molecule Types, Malaria 60

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports